Sharp Daily
No Result
View All Result
Monday, June 15, 2026
  • Home
  • News
    • Politics
  • Business
    • Banking
  • Investments
  • Technology
  • Startups
  • Real Estate
  • Features
  • Appointments
  • About Us
    • Meet The Team
Sharp Daily
  • Home
  • News
    • Politics
  • Business
    • Banking
  • Investments
  • Technology
  • Startups
  • Real Estate
  • Features
  • Appointments
  • About Us
    • Meet The Team
No Result
View All Result
Sharp Daily
No Result
View All Result
Home News

Pharmacy and Poisons Board Flags Diclofenac Painkiller

Editor SharpDaily by Editor SharpDaily
May 20, 2022
in News
Reading Time: 2 mins read
Diclofenac

[Photo/ Courtesy]

The Pharmacy and Poisons Board has flagged ‘Non-Steroidal Anti-Inflammatory Drugs’ (NSAIDs), specifically Diclofenac for pain management.

Diclofenac is a widely used medicine for relieving pain and inflammation, particularly in painful conditions such as arthritis.

“NSAIDs as a class, if used at high dose and for long periods, are associated with an increased risk of blood clots in the arteries especially in patients with underlying heart or circulatory conditions or with certain cardiovascular risk factors, which in some cases has led to heart attack or stroke,” the board said.

Read: Zimbabwe Commissions Ksh3 Billion Medicinal Cannabis Farm

RELATEDPOSTS

Pharmacy board clears Mefenamic Acid suspension for market distribution

March 18, 2025

Pharmacy and poisons board issues advisory on safe handling of health products

March 12, 2025

The board says there is a small risk of heart attack or stroke in patients taking systemic diclofenac regularly, especially at high doses (150 mg daily) and for long periods.

“Use of diclofenac is no longer recommended for patients with history of a heart attack or stroke, heart failure, blockages to blood vessels to the heart or brain or have had an operation to clear or bypass such blockages, or circulatory problems that restrict blood flow to your limbs. If you smoke or have other risk factors such as high blood pressure, high blood cholesterol, diabetes, your doctor will need to assess if you should use diclofenac and the best way to take it,” the board says.

Read: Hisa Joins NVIDIA Inception

If you are on long-term diclofenac treatment you will need to have your treatment reviewed to ensure that it is still right for you. You are advised to speak to your prescriber at your next scheduled appointment.

“You should not stop taking your treatment without talking to your healthcare professional. If you have any questions, speak with your healthcare professional. The Board advises the public against self-medication with painkillers, especially diclofenac. Diclofenac, should only be dispensed or used upon prescription by a duly qualified healthcare professional,” the board added.

Read: Independent Post-Retirement Medical Schemes To Be Licensed -RBA

Previous Post

Uhuru’s Cousin Ngengi Muigai Loses Fight Over 443-acre Land In Thika

Next Post

One Person Likely To Die From Hunger Every 48 Seconds In East Africa

Editor SharpDaily

Editor SharpDaily

The latest in business, real estate, education, investments, tech and entrepreneurship, brought to you daily. Reach us through thesharpdaily@gmail.com

Related Posts

News

Understanding market capitalization and its importance in investment analysis

June 15, 2026
Banking

CBK moves to expand emergency lending powers as Kenya strengthens banking sector stability

June 15, 2026
News

June 12, 2026
News

Where Fintech Companies Actually Make Their Real Profits: Beyond Payments and Transaction Fees

June 12, 2026
News

Why Revenue Growth in Fintech Can Be Misleading: The Hidden Economics Behind Digital Payments

June 12, 2026
News

Finance bill 2026: key tax reforms and economic impact in kenya

June 12, 2026

LATEST STORIES

Understanding market capitalization and its importance in investment analysis

June 15, 2026

CBK moves to expand emergency lending powers as Kenya strengthens banking sector stability

June 15, 2026

Kenya Airways seeks Sh194 Billion to rescue itself from debt crisis

June 15, 2026

June 12, 2026

Where Fintech Companies Actually Make Their Real Profits: Beyond Payments and Transaction Fees

June 12, 2026

Why Revenue Growth in Fintech Can Be Misleading: The Hidden Economics Behind Digital Payments

June 12, 2026

Finance bill 2026: key tax reforms and economic impact in kenya

June 12, 2026

INVISIBLE TRANSACTIONS: THE FUTURE OF PAYMENTS

June 12, 2026
  • About Us
  • Meet The Team
  • Careers
  • Privacy Policy
  • Terms and Conditions
Email us: editor@thesharpdaily.com

Sharp Daily © 2024

No Result
View All Result
  • Home
  • News
    • Politics
  • Business
    • Banking
  • Investments
  • Technology
  • Startups
  • Real Estate
  • Features
  • Appointments
  • About Us
    • Meet The Team

Sharp Daily © 2024